A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine (PALMIRE)

Chronic inflammatory pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and interstitial lung diseases (ILD) are characterised by lung inflammation and remodelling. Clinical, functional, microbiological, biological, pathological and prognostic features are highly variable and heterogeneous. Several phenotypes have been described within the same pathology, as similar phenotypic traits between different pathologies, or the coexistence of components of several diagnoses in the same patient, suggesting shared underlying mechanisms that could represent new therapeutic targets, beyond the initial medical diagnosis.

The objectives of this prospective study are to analyze the phenotypic characteristics (clinical, demographic, biological, morphological, pathological, and microbiological characteristics) together with respiratory exposures and underlying mechanisms involving airway epithelium and inflammation processes in a cohort of patients diagnosed with asthma, COPD, bronchiectasis, CF, PCD and ILD.

Study Overview

• Status: Recruiting
• Conditions: Bronchiectasis; Chronic Obstructive Pulmonary Disease; Asthma; Cystic Fibrosis; Primary Ciliary Dyskinesia
• Intervention / Treatment: Other: Non applicable

Detailed Description

The cohort for inflammatory respiratory diseases: from phenotyping to personalised medicine (The PALMIRE project) is a monocentric study conducted at the University Hospital of Reims, France.

Study Population :

Adult patients (>18 year-old) followed at the University Hospital of Reims and diagnosed with asthma, COPD, bronchiectasis, CF, PCD, and IPF will be considered for inclusion. Patients will sign an informed consent for inclusion. Exclusion criteria include "subjects protected by the law" as required by the French authorities. Control patients with no respiratory diseases after clinical and pulmonary function tests assessment will also be included. The expected number of patients included is 470 (Asthma, n=100; COPD, n=150; bronchiectasis, n=50; CF, n=60; PCD, n=30; ILD, n=30; controls, n=50). Inclusion will be conducted for 60 months from July 2025 to July 2030.

Study Procedures:

For all asthma, COPD, bronchiectasis, CF, PCD, and IPF patients included, data will be registered at inclusion, and at follow-up visits for 10 years. Patients will be followed-up as usual care with no specific therapeutic intervention. For control patients, data will be registered at inclusion with no follow-up.

The recorded data will include demographics, history of respiratory disease and comorbidities, respiratory symptoms, results of lung function tests and CT-scan, microbiological and pathological features of respiratory sampling when performed.

Data Analysis:

Data will be registered in a centralized anonymized database. The characteristics of the patients will be described as mean and standard deviation for quantitative data and as number and percentages for qualitative data. Comparisons and associations between groups and variables will be analyzed by Student, Wilcoxon, Chi2, Fischer exact, and Spearman tests as applicable. A p<0.05 will be considered as significant. Multivariate and longitudinal statistical models will be used to identify clusters of patients with shared endotypes. Machine learning approaches will be employed to integrate multi-omic data and generate predictive models for disease trajectories and treatment responses.

Significance:

This study should help better understand the pathogenesis and heterogeneity of chronic respiratory diseases by integrating the analysis of phenotypic and endotypic characteristics of patients.

• Study Type: Observational
• Enrollment (Estimated): 470

Contacts and Locations

• Study Contact: Name: Jeanne-Marie PEROTIN-COLLARD; Phone Number: 0033 03 10 73 67 63; Email: jmperotin-collard@chu-reims.fr
• Study Contact Backup: Name: Gaëtan DESLEE; Phone Number: 0033 03 26 78 76 11; Email: gdeslee@chu-reims.fr

Study Locations

• France
  • Reims, France, 51092
    • Recruiting
    • Chu Reims
    • Contact: Damien JOLLY; Phone Number: 33 326788472; Email: djolly@chu-reims.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Adult patients (≥18 years old) followed for chronic inflammatory respiratory diseases (asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung diseases) at the Respiratory Medicine Department of CHU Reims. Healthy control subjects without diagnosed respiratory disease will also be included.

Description

Inclusion Criteria:

• Age ≥ 18 years
• Follow-up for one of the following conditions: asthma, COPD, bronchiectasis (DDB), cystic fibrosis (CF), primary ciliary dyskinesia (PCD), or interstitial lung diseases (ILD)
• Healthy volunteers (controls)

Exclusion Criteria:

• Subjects protected by law (e.g., legal incapacity)
• Any condition preventing informed consent or participation

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
pheno-endotypes of inflammatory respiratory disease	Number of subjects in each of the identified pheno-endotypes of inflammatory respiratory disease	Baseline

Secondary Outcome Measures

Outcome Measure	Time Frame
Forced expiratory volume in one second ( FEV1)	10 years
Forced Vital Capacity ( FVC )	10 years
Total Lung Capacity (TLC)	10 years
Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)	10 years
6 minutes walking distance	10 years
Modified Medical Research Council Dyspnea Scale (mMRC dyspnea score)	10 years
Asthma Control Test (ACT questionnaire score)	10 years
Cough and Sputum Assessment Questionnaire (CASA-Q questionnaire score)	10 years
Asthma Quality of Life Questionnaire (AQLQ score)	10 years
St George's Respiratory Questionnaire (SGRQ score)	10 years

Collaborators and Investigators

• Sponsor: CHU de Reims

Study record dates

Study Major Dates

• Study Start (Actual): September 15, 2025
• Primary Completion (Estimated): September 15, 2030
• Study Completion (Estimated): September 15, 2040

Study Registration Dates

• First Submitted: June 10, 2025
• First Submitted That Met QC Criteria: November 27, 2025
• First Posted (Actual): December 10, 2025

Study Record Updates

• Last Update Posted (Actual): February 20, 2026
• Last Update Submitted That Met QC Criteria: February 18, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Bronchiectasis; Remodeling; Airway epithelium; Exposome; Primary ciliary dyskinesia; Airway microbiota
• Additional Relevant MeSH Terms: Ciliopathies; Pathologic Processes; Chronic Disease; Disease Attributes; Genetic Diseases, Inborn; Immune System Diseases; Respiratory Tract Diseases; Digestive System Diseases; Lung Diseases; Infant, Newborn, Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Pancreatic Diseases; Congenital Abnormalities; Otorhinolaryngologic Diseases; Abnormalities, Multiple; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Pathological Conditions, Signs and Symptoms; Pulmonary Disease, Chronic Obstructive; Asthma; Ciliary Motility Disorders; Cystic Fibrosis; Bronchiectasis
• Other Study ID Numbers: PL25060*

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No